Kennedy Ferruggia, Assistant Editor

FDA approves semaglutide for treating MASH, offering new hope for affected individuals.

RSV vaccination rates among older adults remain low despite new vaccines, highlighting disparities in uptake and the need for targeted outreach.

Weight loss before IVF enhances pregnancy chances for women with obesity, potentially improving reproductive outcomes and fertility success rates.

NRX-100 receives FDA fast track designation, offering hope for treating suicidal ideation in depression and bipolar disorder, addressing a critical health crisis.

Intranasal insulin shows promise in targeting memory regions of the brain, offering new hope for Alzheimer disease treatment in older adults.

RSV poses a serious risk to older adults in long-term care, highlighting the need for effective outbreak management and infection control strategies.

Promoting heart health in children reduces obesity and chronic disease risks, ensuring better overall well-being into adulthood.

The FDA expands tocilizumab-anoh's approval for treating cytokine release syndrome (CRS), enhancing treatment options for patients aged 2 and older.

Brad Cochran of Cardinal Health explains the One Voice Initiative, which aims to bolster independent pharmacies.

Donanemab-azbt shows sustained benefits in slowing cognitive decline in Alzheimer disease, emphasizing the value of early intervention and treatment.

Research reveals body fat percentage and waist circumference are more accurate predictors of mortality risk than BMI, highlighting flaws in traditional weight assessments.

Researchers reveal that saliva tests for insulin levels offer a noninvasive method to predict type 2 diabetes and obesity risks effectively.

FDA approves inclisiran as a monotherapy to effectively lower low-density lipoprotein cholesterol in adults with hypercholesterolemia, enhancing heart disease prevention strategies.

New research reveals that GLP-1 receptor agonists like semaglutide may significantly reduce stroke impacts and improve recovery outcomes.

RSV hospitalization in older adults links to increased cardiovascular events, highlighting the need for vigilant monitoring and vaccination strategies.

Luspatercept shows promise in reducing transfusion dependence for myelofibrosis-associated anemia, despite not meeting primary trial end points.

Astegolimab shows promise in reducing chronic obstructive pulmonary disease (COPD) exacerbations, offering hope for improved management of this debilitating lung disease.

A new study reveals that individuals with type 2 diabetes (T2D) face significant financial hardships, impacting their health and medication adherence.

FDA places clinical hold on Sarepta's Elevidys gene therapy after safety concerns, but ambulatory patients regain access amid ongoing investigations.

Discover groundbreaking FDA approvals for HIV prevention, targeted treatments, and OTC allergy relief, enhancing patient care and access to essential medications.

Experts discuss HIV management challenges, including HBV coinfections, anal cancer risks, and weight gain, highlighting innovative treatment strategies.

FDA approves lonapegsomatropin for once-weekly treatment of growth hormone deficiency, offering a promising alternative for improved patient adherence and outcomes.

GLP-1 receptor agonists show promise in improving survival rates for older patients with cancer who have type 2 diabetes (T2D), highlighting their potential in oncology.

RSV outbreaks pose significant risks globally, highlighting the urgent need for targeted vaccination and treatment strategies to protect vulnerable populations.

Insights from the American Diabetes Association 85th Scientific Sessions.

UPMC Health Plan enhances COPD care through personalized treatment, telemedicine, and comprehensive support, ensuring optimal patient outcomes and adherence.

UPMC Health Plan enhances COPD care through a multidisciplinary approach, leveraging telehealth, education, and pharmacist-led programs to optimize patient outcomes.

Different dietary strategies, including intermittent energy restriction, enhance weight loss and blood sugar control in those with type 2 diabetes (T2D) and obesity.

GLP-1 anti-obesity medications enhance testosterone levels, aiding weight management and improving health outcomes for those with obesity and type 2 diabetes (T2D).

Long-term obesity accelerates aging in young adults, increasing risks for cardiovascular diseases and metabolic dysfunction.